The estimated Net Worth of Vijay Sabesan is at least $1.2 Миллион dollars as of 12 December 2019. Mr. Sabesan owns over 1,027 units of Theravance Biopharma Inc stock worth over $1,176,549 and over the last 6 years he sold TBPH stock worth over $21,598. In addition, he makes $0 as Senior Vice President - Technical Operations at Theravance Biopharma Inc.
Sign up
Mr. Sabesan TBPH stock SEC Form 4 insiders trading
Vijay has made over 1 trades of the Theravance Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,027 units of TBPH stock worth $21,598 on 12 December 2019.
The largest trade he's ever made was selling 1,027 units of Theravance Biopharma Inc stock on 12 December 2019 worth over $21,598. On average, Vijay trades about 68 units every 0 days since 2019. As of 12 December 2019 he still owns at least 145,253 units of Theravance Biopharma Inc stock.
You can see the complete history of Mr. Sabesan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vijay Sabesan biography
Vijay Sabesan serves as Senior Vice President - Technical Operations of the Company. He has served as our Senior Vice President of Technical Operations since February 2019, prior to which he served as Vice President of Technical Operations since February 2017 and Vice President of Process R&D since February 2016. He joined the company in June 2014 in from Innoviva as Senior Director of Process R&D. With Innoviva from 2004 to June 2014, he held various positions, ultimately serving as the Senior Director of Process R&D. Prior to joining Innoviva, Mr. Sabesan worked in the chemical process development group at Schering-Plough Research Institute from 1997 to 2004. Mr. Sabesan has a B.Tech. in Chemical Engineering from the Indian Institute of Technology, Madras, and an M.S. in Chemical Engineering from Rutgers University.
How old is Vijay Sabesan?
Vijay Sabesan is 47, he's been the Senior Vice President - Technical Operations of Theravance Biopharma Inc since 2019. There are 25 older and no younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
What's Vijay Sabesan's mailing address?
Vijay's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BLVD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Theravance Biopharma Inc
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, и Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
What does Theravance Biopharma Inc do?
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
What does Theravance Biopharma Inc's logo look like?
Complete history of Mr. Sabesan stock trades at Theravance Biopharma Inc
Theravance Biopharma Inc executives and stock owners
Theravance Biopharma Inc executives and other stock owners filed with the SEC include:
-
Rick Winningham,
Chairman of the Board, Chief Executive Officer -
Andrew Hindman,
Chief Financial Officer, Senior Vice President -
Bradford Shafer,
Executive Vice President, General Counsel, Secretary -
Brett Haumann,
Senior Vice President, Clinical Development and Chief Medical Officer -
Frank Pasqualone,
Senior Vice President and Chief Commercial Operations Officer -
Philip Worboys,
Senior Vice President - Research and Translational Science -
Rick E. Winningham M.B.A.,
Chairman & CEO -
Andrew Asa Hindman,
Sr. VP & CFO -
Bradford J. Shafer,
Exec. VP, Gen. Counsel & Sec. -
Andrew Asa Hindman M.B.A,
Sr. VP & CFO -
Rhonda F. Farnum,
Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs -
William Young,
Lead Independent Director -
Burton Malkiel,
Independent Director -
Donal O'Connor,
Independent Director -
Dean Mitchell,
Independent Director -
Susan Molineaux,
Independent Director -
Eran Broshy,
Independent Director -
Laurie Alsup,
Independent Director -
George Whitesides,
Independent Director -
Robert Gunderson,
Director -
Deepika Pakianathan,
Independent Director -
Vijay Sabesan,
Senior Vice President - Technical Operations -
Kenneth Pitzer,
Senior Vice President - Product Strategy and Commercial Planning -
Ann Brady,
President - Theravance Biopharma Ireland Limited -
Dr. Ann B. Brady Ph.D.,
Pres of Theravance Biopharma Ireland Limited -
Dr. Richard A. Graham Ph.D.,
Sr. VP of Devel. -
Daniel Long,
Head of Medicinal Chemistry -
Dr. Kenneth R. Pitzer,
Sr. VP of Product Strategy & Commercial Planning -
Dr. Phillip D. Worboys,
Sr. VP of Research & Translational Science -
Dennis O. Driver,
Sr. VP of HR, Organizational and Leadership Devel. -
Gail B. Cohen,
VP of Corp. Communications & Investor Relations -
Jeremy T Grant,
-
Renee D Gala,
VP-Finance -
Peter S Ringrose,
Director -
Junning Lee,
Sr. VP, Technical Operations -
Sharathchandra S Hegde,
SVP, Research -
Henrietta Fore,
Director -
Shehnaaz Suliman,
SVP, Corp Dev & Strategy -
Jeffrey David Jonker,
Senior VP, Corp. & Bus. Dev. -
Michael G Atieh,
Director -
Leonard M Blum,
Sr VP, Chief Comm. Officer -
Inc. Innoviva,,
10% owner -
Mathai Mammen,
SVP, Research & Early Clin Dev -
Rhonda Farnum,
SVP, COMM & MEDICAL AFFAIRS -
Richard A Graham,
SVP, RESEARCH & DEVELOPMENT -
Plc Gsk,
-
Aziz Sawaf,
SVP & CHIEF FINANCIAL OFFICER -
Brett A. Grimaud,
SVP, GEN COUNSEL AND SECRETARY -
Susannah Gray,
-
Aine Miller,
SVP, DEV & HEAD OF IRE OFFICE -
Eli Samaha,
10% owner